Skip to Content

Safyral Approval History

FDA Approved: Yes (First approved December 16, 2010)
Brand name: Safyral
Generic name: drospirenone, ethinyl estradiol and levomefolate calcium
Dosage form: Tablets
Company: Bayer HealthCare Pharmaceuticals, Inc.
Treatment for: Birth Control

Safyral (drospirenone, ethinyl estradiol and levomefolate calcium) is an estrogen/progestin combined oral contraceptive containing a folate, indicated for use by women to prevent pregnancy, and to raise folate levels in women who choose to use an oral contraceptive for contraception.

Development History and FDA Approval Process for Safyral

DateArticle
Dec 17, 2010Approval FDA Approves Safyral - Oral Contraceptive That Also Raises Folate Levels

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide